Northside Hospital Cancer Institute Immunotherapy Program in collaboration with Bristol Myers Squibb is offering a Phase II, open label, multicenter study of BMS-986393, a GPRC5D-directed CAR T Cell therapy for patients with relapsed or refractory Multiple Myeloma. BMS-986393, is an investigational chimeric antigen receptor (CAR) T cell product targeting GPRC5D.

G protein-coupled receptor class C, group 5, member D (GPRC5D) represents a new target in the treatment of multiple myeloma (MM). GPRC5D is highly expressed in plasma cells of MM patients, and overexpression of GPRC5D is associated with a poor prognosis. 

If you have any questions, would like to discuss study logistics, or the eligibility of any patients, please contact Caitlin Guzowski, NH BMT/Leukemia Clinical Research Manager, at 404-851-8523 or caitlin.guzowski@northside.com

Primary Objective

To evaluate the efficacy of BMS-986393 in participants with quadruple class exposed R/R MM having received at least 4 prior lines of treatment.

Key Inclusion Criteria

• Must have received at least 4 classes of MM treatment (including an IMiD, PI, anti-CD38 mAb, and anti-BCMA therapy), and at least 3 prior LOT
• Documented disease progression during or after last anti-myeloma regimen (as per IMWG)

Key Exclusion Criteria

• Active or history of central nervous system involvement with MM
• Active systemic fungal, bacterial, viral, or other infection despite appropriate anti-infective treatment at the time of leukapheresis
• Received any prior therapy directed at G protein-coupled receptor class C, group 5, member D (GPRC5D) or has received other prior treatment for MM without the required washout prior to leukapheresis
• Other protocol-defined Inclusion/Exclusion criteria apply